Hypertension:急性心肌梗死后高血压、微血管病变与预后

2018-07-17 xing.T MedSci原创

由此可见,严重的进行性微血管损伤参与了高血压和急性心肌梗塞病史患者的病理生理学和预后。

近日,心血管权威杂志Hypertension上发表了一篇研究文章,该研究的主要目的是探究急性ST段抬高心肌梗死患者与高血压病史相关的微血管损伤的病理生理学机制。

研究人员使用侵入性和非侵入性微血管损伤指标、2天和6个月的心脏磁共振成像进行了一项队列研究,并评估了长期的健康结局。

340例急性心肌梗死患者(平均年龄为59[12]岁;血压为135[25]/79[14]mmHg;男性占237人[73%],先天性高血压占105人[32%])在紧急经皮冠状动脉介入治疗期间进行了前瞻性研究。与既往没有高血压的患者相比,高血压患者年龄较大(63 [12]岁 vs. 57 [11]岁; P<0.001),吸烟者比例较低(52 [50%] vs. 144 [66%]; P=0.007)。冠状动脉血流、罪犯动脉内的微血管阻力、梗塞病变、炎症(C-反应蛋白和白细胞介素-6)与高血压无关。与既往没有高血压的患者相比,高血压患者在基线6个月时左心室射血分数改善较少(5.3[8.2]% vs. 7.4 [7.6]%; P=0.040)。出院后(中位随访4年),既往高血压是心肌梗死后2天心肌出血(1.81 [0.98-3.34]; P = 0.059)和全因死亡或心力衰竭(n=47次事件,n=24伴有高血压; 2.53[1.28-4.98]; P=0.007)存在多变量相关。

由此可见,严重的进行性微血管损伤参与了高血压和急性心肌梗塞病史患者的病理生理学和预后。

原始出处:

David Carrick,et al. Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction.Hypertension.2018. https://doi.org/10.1161/HYPERTENSIONAHA.117.10786

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038947, encodeId=ca9d203894ea3, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 21 05:03:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727435, encodeId=e7fc1e274352e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 30 05:03:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644690, encodeId=846d1644690ce, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Dec 16 04:03:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365346, encodeId=fcae1365346d3, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391082, encodeId=b76d139108282, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492039, encodeId=567c1492039ab, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501313, encodeId=fa4c1501313ca, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038947, encodeId=ca9d203894ea3, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 21 05:03:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727435, encodeId=e7fc1e274352e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 30 05:03:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644690, encodeId=846d1644690ce, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Dec 16 04:03:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365346, encodeId=fcae1365346d3, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391082, encodeId=b76d139108282, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492039, encodeId=567c1492039ab, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501313, encodeId=fa4c1501313ca, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-10-30 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038947, encodeId=ca9d203894ea3, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 21 05:03:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727435, encodeId=e7fc1e274352e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 30 05:03:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644690, encodeId=846d1644690ce, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Dec 16 04:03:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365346, encodeId=fcae1365346d3, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391082, encodeId=b76d139108282, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492039, encodeId=567c1492039ab, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501313, encodeId=fa4c1501313ca, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2038947, encodeId=ca9d203894ea3, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 21 05:03:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727435, encodeId=e7fc1e274352e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 30 05:03:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644690, encodeId=846d1644690ce, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Dec 16 04:03:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365346, encodeId=fcae1365346d3, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391082, encodeId=b76d139108282, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492039, encodeId=567c1492039ab, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501313, encodeId=fa4c1501313ca, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-19 mgqwxj
  5. [GetPortalCommentsPageByObjectIdResponse(id=2038947, encodeId=ca9d203894ea3, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 21 05:03:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727435, encodeId=e7fc1e274352e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 30 05:03:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644690, encodeId=846d1644690ce, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Dec 16 04:03:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365346, encodeId=fcae1365346d3, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391082, encodeId=b76d139108282, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492039, encodeId=567c1492039ab, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501313, encodeId=fa4c1501313ca, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2038947, encodeId=ca9d203894ea3, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 21 05:03:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727435, encodeId=e7fc1e274352e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 30 05:03:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644690, encodeId=846d1644690ce, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Dec 16 04:03:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365346, encodeId=fcae1365346d3, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391082, encodeId=b76d139108282, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492039, encodeId=567c1492039ab, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501313, encodeId=fa4c1501313ca, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2038947, encodeId=ca9d203894ea3, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Apr 21 05:03:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727435, encodeId=e7fc1e274352e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 30 05:03:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644690, encodeId=846d1644690ce, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Dec 16 04:03:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365346, encodeId=fcae1365346d3, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391082, encodeId=b76d139108282, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492039, encodeId=567c1492039ab, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501313, encodeId=fa4c1501313ca, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 19 05:03:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]

相关资讯

JAHA:急性心肌梗死患者体重指数与心脏猝死

由此可见,肥胖(BMI≥27.5kg/ m2)与心肌梗死患者的SCD风险相关,尽管在全因死亡率方面存在肥胖悖论。

无痛性急性心肌梗死的原因鉴别和诊断!

近年来,心血管疾病发病率居高不下,尤其是急性心肌梗死患者的数量呈现上升趋势。急性心肌梗死是临床一种常见疾病,急性心肌梗死患者大部分具有典型而明显的症状,表现为心前区、胸骨后疼痛同时伴有胸闷等......

JAHA:替卡格雷在急性心肌梗死中的应用!

由此可见,当前的分析显示出院时给与替卡格雷的数量显著增加,同时使用低剂量阿司匹林的依从性也很高。

病例:一例异常的急性心肌梗死心脏破裂

近年,急性心肌梗死患者呈明显上升趋势。而冠脉造影被大众普遍接受为了解急性心肌梗死患者心血管状况的金标准。但是对于急危重的疾病,在相信检查结果的同时,更要以患者健康及生命为重心,多一手准备。今天分享给大家的病例就是一例这样的案例。 过度劳累导致的胸痛晕厥 患者是一个45岁的男性,是一个从事长途货运行业的司机,因接班同事家中有急事请假而持续开车36小时,2小时前到达本市时出现胸痛情况,持续

给力!医闹索赔180万,这个医院霸气回应!

硬气!为这家医院点赞,不是所有的“医闹”都能得到赔偿。

JACC Cardiovasc Imag:早期无症状MI与临床AMI患者不良预后相关

一项观察性研究的数据显示,先前无症状或未被识别的心肌梗死(UMI)在临床上较为常见,其与临床急性心肌梗死(AMI)患者的不良预后独立相关。